{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Esophageal+SCC&page=5", "query": { "condition": "Esophageal SCC", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 145, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Esophageal+SCC&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Esophageal+SCC&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T09:36:50.823Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05945823", "title": "Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer", "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Cancer", "Siewert Type 1 GEJ Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "Futibatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Levoleucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2023-07-13", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-10-11T09:36:50.823Z", "location_count": 16, "location_summary": "Santa Monica, California • Denver, Colorado • Miami Beach, Florida + 13 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05945823" }, { "nct_id": "NCT00002711", "title": "Combination Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "chemotherapy", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "low-LET electron therapy", "type": "RADIATION" }, { "name": "low-LET photon therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "1995-10", "completion_date": "2000-10", "has_results": false, "last_update_posted_date": "2013-07-03", "last_synced_at": "2026-10-11T09:36:50.823Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002711" }, { "nct_id": "NCT04510129", "title": "A Multicenter Cancer Biospecimen Collection Study", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Cancer of Head and Neck", "Lung Cancer, Nonsmall Cell", "Small-cell Lung Cancer", "Urothelial Carcinoma", "Gastroesophageal Junction Adenocarcinoma", "Cervical Cancer", "Esophageal Squamous Cell Carcinoma", "Triple Negative Breast Cancer", "Hepatocellular Carcinoma", "Renal Cell Carcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "OncoPrism™ assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Cofactor Genomics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1650, "start_date": "2020-02-05", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2025-03-12", "last_synced_at": "2026-10-11T09:36:50.823Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04510129" }, { "nct_id": "NCT07730021", "title": "A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "ASP388B", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 392, "start_date": "2026-09-02", "completion_date": "2030-05-31", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-11T09:36:50.823Z", "location_count": 2, "location_summary": "Lake Success, New York • Fairfax, Virginia", "locations": [ { "city": "Lake Success", "state": "New York" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07730021" }, { "nct_id": "NCT05104567", "title": "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oesophageal Squamous Cell Carcinoma", "Gastric Cancer", "Hepatocellular Carcinoma", "Colorectal Cancer", "Oesophageal Adenocarcinoma" ], "interventions": [ { "name": "THOR-707", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 138, "start_date": "2021-12-09", "completion_date": "2024-09-09", "has_results": true, "last_update_posted_date": "2025-09-24", "last_synced_at": "2026-10-11T09:36:50.823Z", "location_count": 3, "location_summary": "Duarte, California • Orlando, Florida • Seattle, Washington", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT05104567" }, { "nct_id": "NCT00258323", "title": "Radiotherapy,Chemotherapy,Before and After Surgery in Advanced Esophageal or Gastroesophageal Junction Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "Iressa", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2005-10", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2015-09-30", "last_synced_at": "2026-10-11T09:36:50.823Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00258323" }, { "nct_id": "NCT03223662", "title": "Metabolomic and BH3 Profiling of Esophageal Cancers: Identification of Novel Assessment Methods of Treatment Response for Precision Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Esophageal Adenocarcinoma", "Esophageal Squamous Cell Cancer", "Esophageal Neoplasms", "Squamous Cell Carcinoma" ], "interventions": [ { "name": "Chemoradiotherapy", "type": "OTHER" }, { "name": "Esophagectomy", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 2, "start_date": "2017-10-31", "completion_date": "2018-07-27", "has_results": true, "last_update_posted_date": "2018-10-30", "last_synced_at": "2026-10-11T09:36:50.823Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03223662" }, { "nct_id": "NCT05799274", "title": "Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers", "Pancreatic Ductal Adenocarcinoma", "Non-small Cell Lung Cancer (NSCLC)", "Esophageal Squamous Cell Carcinoma", "Cervical Cancer", "Endometrial Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "RAD301 ([68Ga]-RAD301)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Radiopharm Theranostics, Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2023-11-09", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-11T09:36:50.823Z", "location_count": 2, "location_summary": "Princeton, New Jersey • The Bronx, New York", "locations": [ { "city": "Princeton", "state": "New Jersey" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05799274" }, { "nct_id": "NCT07218003", "title": "A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Cervical Cancer", "Head and Neck Squamous Cell Cancer", "Triple Negative Breast Cancer (TNBC)", "Urothelial Carcinoma Bladder", "Gastroesophageal Junction (GEJ) Adenocarcinoma", "Esophageal Squamous Cell Cancer", "Gastric Cancer", "Cancer", "Solid Tumors (Phase 1)" ], "interventions": [ { "name": "RNDO-564", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rondo Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2025-11-17", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-11T09:36:50.823Z", "location_count": 11, "location_summary": "San Francisco, California • New Haven, Connecticut • Grand Rapids, Michigan + 8 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07218003" }, { "nct_id": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Astrocytoma, IDH-Mutant", "Glioblastoma, IDH-wildtype", "Brain Metastases, Adult", "Cervical Cancer", "Colorectal Cancer", "Esophageal Cancer", "Esophageal Squamous Cell Carcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Head and Neck Squamous Cell Carcinoma", "Melanoma", "Merkel Cell Carcinoma", "Microsatellite Instability-High Solid Malignant Tumor", "Mismatch Repair Deficient Solid Malignant Tumor", "Microsatellite Instability-High Colorectal Cancer", "Mismatch Repair Deficient Colorectal Cancer", "Non-small Cell Lung Cancer", "Renal Cell Carcinoma", "Small Cell Lung Cancer", "Squamous Cell Carcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "NEO212 Oral Capsule", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "FOLFIRI Protocol", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neonc Technologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2023-11-01", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-11T09:36:50.823Z", "location_count": 8, "location_summary": "Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06047379" } ] }